A novel chromatography method for high purity production of Recombinant human parathyroid hormone from E. coli.

Human parathyroid hormone (hPTH) shows great potential as a therapeutic option for osteoporosis in patients who do not respond sufficiently to conventional therapies. We utilize recombinant DNA technology to enhance the drug development process and introduce a state-of-the-art purification protocol for the first 34 residues of human parathyroid hormone (hPTH), as these residues are responsible for the majority of its hormonal activity. Typically, the purification of recombinant human parathyroid hormone has relied on His-Tag fusion partners using Ni²⁺-chelating chromatography. This is the first time ion exchange chromatography has been used for the soluble PTH form, and no reports of ion exchange chromatography for this purpose have been documented. SUMO-tag technology and a three-step chromatography process were used to purify recombinant human parathyroid hormone [rhPTH1-34 on a large scale from Escherichia coli. The rhPTH (1-84) construct was cloned into E. coli host cells and expressed at fermenter scale with a 5-liter volume. The SUMO-hPTH1-34 fusion protein was extracted and purified using a Capto™ adhere column. The N-terminus of SUMO-hPTH was specifically cleaved with SUMO protease, after which rhPTH was further purified through sequential chromatography on Capto adhere and Capto SP columns. Our purification procedure for rhPTH from E. coli achieved over 98% purity, as confirmed by SDS-PAGE and RP-HPLC. This study demonstrates that the purified rhPTH1-34 meets the purity standards for commercial drug specifications. We propose that our three-step chromatography process effectively purifies active rhPTH1-34 derived from E. coli. Compared with IMAC and RPC, the purification steps used in this article are more cost-effective and environmentally friendly. This methodology has the potential to be scaled up in an industrial setting.